NCT00677092View on ClinicalTrials.gov

Pilot Study of Imatinib Mesylate to Treat Nephrogenic Systemic Fibrosis

PHASE2CompletedINTERVENTIONAL

Enrollment

12

Participants

Timeline

Start Date

December 31, 2007

Primary Completion Date

July 31, 2009

Study Completion Date

July 31, 2009

Conditions

Nephrogenic Systemic Fibrosis

Interventions

DRUG

Imatinib mesylate

400 mg p.o. daily for 4 months. Dosage was reduced to 200 mg if participants develop gastrointestinal intolerance or alopecia.

Trial Locations (1)

02114

Massachusetts General Hospital, Boston

Sponsors

Collaborators (1)

Novartis Pharmaceuticals

All Listed Sponsors

collaborator

Novartis Pharmaceuticals

INDUSTRY

lead

Massachusetts General Hospital

OTHER